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Abstract
Objectives—Proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a newly 
recognized entity that must be differentiated from eosinophilic esophagitis (EoE). Little is known 
about this condition. We aimed to determine the prevalence of PPI-REE and EoE in patients 
undergoing upper endoscopy, and determine features that distinguish the two groups.
Methods—This prospective study conducted at University of North Carolina from 2009–2011 
enrolled consecutive adult patients undergoing outpatient upper endoscopy. Subjects had 
esophageal biopsies to quantify the maximum eosinophil count per high-powered field (eos/hpf; 
hpf = 0.24mm2). If biopsies revealed ≥15 eos/hpf, subjects were treated with twice daily PPI for 8 
weeks and endoscopy was repeated. If ≥15 eos/hpf persisted despite PPI therapy, EoE was 
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diagnosed. If there were <15 eos/hpf, PPI-REE was diagnosed. The proportion of patients in each 
group was calculated, and patients with EoE and PPI-REE were compared.
Results—Of the 223 subjects enrolled, 173 had dysphagia and 50 did not. Of those with 
dysphagia, 66 (38%) had ≥15 eos/hpf. After the PPI trial, 40 (23%) were confirmed to have EoE, 
and 24 (14%) had PPI-REE. Of those without dysphagia, 2 (4%) had ≥15 eos/hpf and after the PPI 
trial, 1 (2%) had EoE. Compared with EoE, PPI-REE patients were more likely to be older and 
male, and less likely to have typical endoscopic findings of EoE. However, none of the individual 
factors was independently predictive of PPI-REE status on multivariable analysis. Similarly, while 
some endoscopic findings were differentially distributed between PPI-REE and EoE, none were 
significantly associated with disease status on multivariable analysis.
Conclusions—Esophageal eosinophilia is common among patients undergoing EGD for 
dysphagia. While EoE was seen in nearly a quarter of patients with dysphagia, PPI-REE was 
almost as common, and accounted for over one-third of those with ≥15 eos/hpf. No clinical or 
endoscopic features independently distinguished PPI-REE from EoE prior to the PPI trial.
Keywords
proton pump inhibitor-responsive esophageal eosinophilia; eosinophilic esophagitis; prevalence; 
endoscopy; dysphagia
Introduction
Eosinophilic esophagitis (EoE) is an immune-mediated clinicopathologic condition 
characterized by symptoms of esophageal dysfunction in the setting of eosinophilic 
inflammation on esophageal biopsy (1, 2). Over the past decade, this condition has become 
increasingly recognized, and it is now frequently encountered in patients undergoing upper 
endoscopy (3–5). However, the finding of esophageal eosinophilia is not specific for EoE. 
The differential diagnosis is relatively broad and can include infections, drug 
hypersensitivity, autoimmune and connective tissue disorders, and hypereosinophilic 
syndrome (1, 2, 6, 7). From a practical standpoint, however, gastroesophageal reflux disease 
(GERD) and proton pump-inhibitor esophageal eosinophilia (PPI-REE) are the most 
commonly encountered conditions that must be distinguished from EoE (1, 2, 8).
In particular, the recent recognition of PPI-REE has complicated the diagnostic algorithm 
for EoE. PPI-REE is the term used to describe patients with esophageal eosinophilia on 
biopsy who respond to a course of PPI therapy. It was first observed in a series of pediatric 
patients (9), and now accounts for at least one third of children and adults with esophageal 
eosinophilia (10–15). While recent guidelines require the exclusion of PPI-REE with a PPI 
trial before a formal diagnosis of EoE can be made (1, 2), it is currently unclear if PPI-REE 
is a subtype of GERD, an EoE phenotype, or an independent condition. In addition, the 
prevalence of PPI-REE has not been prospectively determined in a cohort in the United 
States. PPI-REE is poorly understood, and predictors that might distinguish EoE from PPI-
REE are unknown.
The aim of this study was to determine the prevalence of PPI-REE and EoE in patients with 
and without dysphagia undergoing upper endoscopy, and to determine if clinical, 
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endoscopic, or histologic features could distinguish the two groups. Based on our 
experience, we hypothesized that no such factors would distinguish PPI-REE from those 
with EoE.
Methods
Study design and patients
This was a prospective cohort study conducted at the University of North Carolina (UNC) 
between 2009 and 2011. Consecutive adult patients (ages 18–80 years) referred for routine 
outpatient esophagogastroduodenoscopy (EGD) were recruited from the two UNC GI 
procedure units. Patients were stratified by indication (dysphagia vs other indications), and 
enrolled in an approximately 3:1 ratio of dysphagia vs non-dysphagia indications, in order to 
enrich the study pool for patients with dysphagia. Subjects were excluded if they had a 
known (prevalent) diagnosis of EoE or a different eosinophilic gastrointestinal disorder 
(EGID), GI bleeding, active anticoagulation, known esophageal cancer, prior esophageal 
surgery, known esophageal varices, medical instability or multiple comorbidities precluding 
enrollment in the clinical opinion of the endoscopist, or inability to read or understand the 
consent form. Subjects provided informed consent and were enrolled prior to the endoscopy. 
This study was approved by the UNC Institutional Review Board.
Subjects with a new (incident) diagnosis of EoE met consensus guidelines (1). Specifically, 
cases were required to have at least one typical symptom of esophageal dysfunction (for 
example dysphagia, food impaction, heartburn, or feeding intolerance); at least 15 
eosinophils per high-power field (eos/hpf) on esophageal biopsy persisting after an 8 week 
PPI trial (20–40 mg twice daily of any of the available agents, prescribed at the discretion of 
the clinician); and other causes of esophageal eosinophilia excluded. While the majority of 
the EoE group included subjects who were PPI-naïve on their index endoscopy (n = 24), 
there were patients who were on high-dose PPI for at least 8 weeks at the time of their index 
endoscopy (n = 17) who did not have pre-PPI endoscopy or histology data available.
Subjects with PPI-REE were required to have at least one typical symptom of esophageal 
dysfunction (for example dysphagia, food impaction, heartburn, or feeding intolerance); at 
least 15 eosinophils per high-power field (eos/hpf) on esophageal biopsy; improvement of 
esophageal eosinophilia to < 15 eos/hpf after an 8 week PPI trial (20–40 mg twice daily of 
any of the available agents, prescribed at the discretion of the patient’s clinician); and 
improvement of symptoms by self-report at the time of the repeat endoscopy. By definition, 
the PPI-REE group included only subjects who were PPI-naïve at the time of their index 
endoscopy and required follow-up endoscopy after the PPI trial.
Clinical and histologic data
Clinical data including demographics, symptoms, and the indications for endoscopy were 
recorded. At the time of enrollment, a blood sample was drawn for the peripheral eosinophil 
count (cells x 109/L) and total IgE level (kU/L). During endoscopy, all endoscopic findings 
were recorded using a standardized case report form. A total of 5 research protocol 
esophageal biopsies were obtained (2 from the proximal, 1 from the mid, and 2 from the 
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distal esophagus) to maximize the sensitivity of EoE diagnosis (16). Additional clinical 
biopsies were taken as needed at the discretion of the endoscopist. Esophageal biopsies were 
reviewed by the study pathologists to determine eosinophil counts according to our 
previously validated protocol (17). In brief, the slides were masked to the clinical case status 
and digitized. Using Aperio ImageScope (Aperio Technologies, Vista, CA), the maximum 
eosinophil density (eosinophils/mm2 [eos/mm2]) was determined after examination of five 
microscopy fields from each of the five biopsies. For purposes of comparison to previous 
studies, eosinophil density was then converted to eosinophil counts (eos/hpf) for an assumed 
hpf size of 0.24 mm2, the size of an average field as reported in the literature (18). The 
eosinophil infiltration was further examined to determine whether it was patchy (localized 
eosinophilia ≥15 eos/hpf in only one hpf in the biopsy) or diffuse (eosinophilic inflammation 
seen in multiple hpfs) throughout the entire biopsy sample, as well as whether the eosinophil 
distribution throughout the mucosa was superficial only, basal only, or diffuse (throughout 
the epithelium). Of note, gastric and duodenal biopsies were also collected and examined to 
exclude co-existing eosinophilic gastritis or gastroenteritis.
Statistical analysis
Characteristics of the study groups were summarized using descriptive statistics, and the 
proportion of EoE cases and PPI-REE subjects were calculated. Bivariate comparisons were 
made between patients with and without esophageal eosinophilia ≥ 15 eos/hpf, and between 
EoE cases and PPI-REE subjects. Chi-square was used for categorical variables and t-tests 
were used for continuous variables. For the comparison between EoE and PPI-REE, baseline 
data from the PPI-naïve visit were used. Thus, patients diagnosed with EoE on an index 
endoscopy while on high-dose PPI were excluded from these comparisons. Multivariable 
logistic regression was used to assess for factors that would independently distinguish PPI-
REE and EoE. Based on the final sample size, different models were constructed with no 
more than 4 covariates.
Results
Patient flow and characteristics of subjects with esophageal eosinophilia
There were 565 patients screened for this study (Figure 1). Of these, 205 were ineligible (26 
were out of the age range, 22 had GI bleeding, 6 had esophageal cancer, 6 had prior 
esophageal resection, 9 had esophageal varices, 2 were actively anticoagulated, 26 had prior 
EoE or EGID, 89 had medical instability/comorbidities, 19 did not speak English and were 
unable to provide consent), 48 were screened but cancelled their endoscopy appointment, 36 
were screened but were unable to be recruited at the time of endoscopy, and 53 refused 
participation.
Of the 223 subjects who were enrolled, 173 had dysphagia and 50 did not have dysphagia. 
Of the 173 patients with dysphagia, 66 (38%) had esophageal eosinophilia with ≥ 15 eos/
hpf. After the PPI-trial, 40 (23%) were confirmed to have EoE, 24 (14%) had PPI-REE, and 
1 (0.6%) had eosinophilic gastroenteritis. Of the 50 patients without dysphagia, 2 (4%) had 
esophageal eosinophilia with ≥ 15 eos/hpf. After the PPI trial, 1 (2%) had EoE and 1 (2%) 
had eosinophilic gastroenteritis.
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There were multiple clinical, endoscopic, and histologic differences between those with and 
without esophageal eosinophilia (Table 1). When compared to subjects without esophageal 
eosinophilia, those with eosinophil counts ≥ 15 eos/hpf were younger (41 vs 54 years; p < 
0.001), more likely to be male (73% vs 37%; p < 0.001), and more likely to be white (92% 
vs 77%; p = 0.006). They were less likely to have a normal endoscopic exam (2% vs 23%; p 
< 0.001), and more likely to have the typical findings of EoE, including esophageal rings, 
strictures, narrowing, linear furrows, crêpe-paper mucosa, and decreased vascularity.
When examining the post-PPI treatment eosinophil counts, there were several histologically 
borderline cases. In the EoE group, there were 3 subjects with an eosinophil count of 16; all 
of the other subjects had counts > 20 eos/hpf. In the PPI-REE group there were 4 patients 
with an eosinophil count of 14 eos/hpf and 4 patients with an eosinophil count of 13 eos/hpf; 
the remainder of the subjects had counts < 10 eos/hpf. In this group, however, these counts 
were substantially decreased from a mean of 90 after the PPI therapy (the pre-PPI individual 
counts were 256, 100, 40, 120, 25, 53, 57, and 49 eos/hpf).
EoE cases and PPI-REE subjects
When the 24 PPI-REE subjects and 41 EoE cases were compared, those with PPI-REE were 
more likely to be older (48 vs 36 years; p < 0.001), male (88% vs 63%; p = 0.04), and have a 
Schatzki’s ring (21% vs 4 %; p = 0.01) (Table 2). They were less likely to have esophageal 
rings (63% vs 100%), narrowing (8% vs 33%; p = 0.03), linear furrows (58% vs 92%; p = 
0.008), and decreased vascularity (0% vs 17%; p = 0.04). There was no difference in the 
maximum pre-PPI-trial eosinophil count between the PPI-REE and EoE groups (58 vs 63 
eos/hpf; p = 0.74). There were also no significant differences in eosinophil distributions. The 
eosinophil infiltration was patchy throughout the biopsy specimen in 61% of the EoE 
subjects as compared with 83% of those with PPI-REE (p = 0.16). In the EoE group, the 
eosinophil mucosal distribution was superficial, basal, and diffuse, in 7%, 24%, and 69%, 
respectively, and in the PPI-REE group it was 27%, 9%, and 63%, respectively (p = 0.17). 
While the peripheral blood eosinophil count was statistically lower in the PPI-REE group, 
levels for both groups were still within the normal range (0.21 vs 0.35 cells x 109/L; p = 
0.01); there were no differences for the total IgE level. After the PPI-trial, the mean 
eosinophil count was 9 eos/hpf in the PPI-REE group (range 0–14 eos/hpf; IQR 4–13 eos/
hpf).
On multivariate analysis, there were no independent clinical, endoscopic, or histologic 
predictors that reliably distinguished PPI-REE from EoE.
Discussion
With the increasing recognition and diagnosis of EoE, esophageal eosinophilia is being 
encountered more frequently (2). While the most common causes of esophageal eosinophilia 
were presumed to be GERD and EoE (7), the recent identification of PPI-REE has 
complicated the diagnostic algorithms and this condition is little understood (1, 2, 9, 12). 
The present study aimed to determine the prevalence of EoE and PPI-REE in patients 
undergoing endoscopy and assess whether clinical, endoscopic, or histologic features could 
distinguish the two groups. There are several key findings. First, esophageal eosinophilia is 
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commonly encountered in the GI procedure unit, with nearly 40% of subjects with 
dysphagia and 4% of patients without dysphagia having ≥ 15 eos/hpf, the current threshold 
required to suspect a diagnosis of EoE. Second, after an 8 week PPI trial, almost one quarter 
of patients with dysphagia and 2% of those without dysphagia, were confirmed to have EoE 
by consensus guidelines. However, more than one third of patients with esophageal 
eosinophilia were found to have PPI-REE. Third, no clinical, endoscopic, or histologic 
feature independently distinguished EoE from PPI-REE prior to the PPI trial.
Several prior studies have assessed the prevalence of EoE in patients undergoing endoscopy. 
The rate has ranged from 6.5% in all patients undergoing endoscopy (4), to 12–15% in 
patients undergoing endoscopy with an indication of dysphagia (3, 5), to more than 50% in 
patients undergoing an endoscopy in the setting of an active food impaction (19, 20). 
However, these studies were conducted before the recognition of PPI-REE, and not all 
subjects diagnosed with EoE had a prior PPI-trial. Therefore, these estimates almost 
certainly include a mix of both EoE and PPI-REE patients. The prevalence of EoE in 
patients undergoing endoscopy for dysphagia in our study is higher than previously reported, 
and may reflect either continuing trends in the increasing incidence of EoE (21), referral bias 
from procedures performed at an academic center, selection bias given that less than half of 
patients screened were enrolled, or a combination of all three. However, even if we assume 
that all of the subjects who were screen failures had normal esophageal biopsies, esophageal 
eosinophilia and EoE would still be quite common in the dysphagia population.
Interestingly, our estimate of the prevalence of the proportion of patients with esophageal 
eosinophilia who responded to a PPI trial, is very similar to other estimates of PPI-REE in 
the literature (Table 3) (10–15, 22–26). The majority of studies on PPI-REE have been 
retrospective, and report that 39–71% of children and adults with esophageal eosinophilia 
have PPI-REE. In the first prospective study examining PPI-REE, Molina-Infante and 
colleagues enrolled 712 adults in Spain undergoing upper endoscopy for any indication, and 
35 (4.9%) had ≥ 15 eos/hpf on esophageal biopsy (12). Subjects were treated with 
rabeprazole 20 mg twice daily for 2 months, and then underwent upper endoscopy. A total 
of 26 (74%) had resolution of esophageal eosinophilia and were classified as PPI-REE. Both 
in this study, and in one by Francis and colleagues where the frequency of PPI-REE was 
61%, baseline reflux testing was not predictive of PPI-REE status (12, 14). Other 
prospective studies in which information can indirectly be inferred about PPI-REE 
prevalence are two clinical trials of fluticasone vs esomeprazole for patients with esophageal 
eosinophilia, where the rates of PPI response were remarkably similar at 33% and 35% (22, 
23).
There are several mechanisms that might explain this response to PPI medications. It is 
possible that in some patients with PPI-REE, the esophageal eosinophilic infiltrate is due to 
GERD, and the mechanism is simply related to decreasing acid exposure (27, 28). Similarly, 
it is possible that PPIs heal damaged epithelial barriers in EoE, thus decreasing antigen 
exposure and reducing eosinophilia (27). It is also possible that PPIs have a direct anti-
eosinophilic/anti-inflammatory effect (29, 30). Others suggest in that PPIs may decrease 
eosinophil degranulation (31).
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Regardless of the mechanism, it is difficult to predict which patients with esophageal 
eosinophilia will respond to PPIs and which will have EoE. In our study, while those with 
PPI-REE were somewhat older and had fewer typical endoscopic findings of EoE, the 
groups were largely indistinguishable and clinical, endoscopic, and histologic factors were 
not predictive after multivariate analysis. These findings are similar to those of other 
investigators (12, 32), as well as recent abstract data showing that eotaxin-3 and Th2 
cytokines were decreased in PPI-REE patients, in patterns similar to what is observed after 
EoE patients are treated with topical steroids (33). Currently, it remains unknown if some 
patients with PPI-REE will eventually be categorized as a subtype of EoE, particularly as 
PPI-REE may change over time; there has been one report of 4 children who developed EoE 
after initially having a PPI response (34).
We have previously reported that EoE and GERD could be distinguished using a 
multivariable analysis of clinical, endoscopic and histologic features (35). The contrast 
between those results and the present study, where EoE and PPI-REE could not be similarly 
differentiated, is notable. We believe that this is explained by differences in the comparator 
groups (GERD vs. PPI-REE). In the first study, GERD patients had to have at least one 
typical symptom of GERD (i.e. heartburn, regurgitation, etc) which was the main indication 
for EGD, consistent biopsy findings (inflammation which could, but did not have to contain, 
eosinophils), and a clinical evaluation which excluded other possible causes. There were no 
restrictions on esophageal eosinophil counts in the GERD patients, but while some in this 
group had eosinophil-predominant inflammation, many had mixed inflammatory infiltrates 
that would not be consistent with EoE, and therefore would not be eligible for the present 
study. In contrast, in the present study, all patients started with a purely eosinophilic 
infiltrate and a clinical picture that was suspicious for EoE. Subjects with GERD-
predominant symptoms and with eosinophils and a mixed inflammatory infiltrate would not 
have been included in the esophageal eosinophilia group. Therefore, the conclusions of the 
studies are different – predictors do exist to separate EoE from GERD patients, but not EoE 
from PPI-REE patients.
This study has limitations that should be considered in interpreting the results. First, it was 
performed in an academic referral center, so the prevalences may not be generalizable to 
other practice settings. However, the features of subjects with esophageal eosinophilia, EoE, 
and PPI-REE are similar to those previously reported and the prevalence of PPI-REE is in 
the same range as other studies. Second, not every subject can be recruited in a PPI-naïve 
state, so some EoE patients had their index endoscopy on PPI. While this limits the sample 
size for baseline PPI-naïve comparisons, a post-hoc sensitivity analysis showed that there 
were no significant differences between EoE patients who had a PPI-naïve baseline 
endoscopy and those who did not. Furthermore, our population is similar to that which 
might be encountered by the practicing clinician, given the ubiquity of PPI use. Third, 
patients found to not have esophageal eosinophilia could be on a PPI at the time of their 
index endoscopy. It is theoretically possible that a proportion of these patients could have 
had unknown esophageal eosinophilia and were then misclassified as normal when they 
actually had PPI-REE. However, this is likely pertinent only for a small number, and if 
misclassification were present, it would bias the differences noted between the study groups 
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towards the null and underestimate the prevalence of PPI-REE. Misclassification could also 
be possible, and would also bias the results towards the null, if many of the subjects had 
borderline post-PPI eosinophil counts that were close to the 15 eos/hpf cutoff. For instance, 
3 EoE subjects had eosinophil counts of 16 eos/hpf, and would have been reclassified with 
just two cells fewer. Fourth, while a symptom response was included in the definition of 
PPI-REE, given that there were no validated symptom measures in EoE available when this 
study was designed, we relied on patient self-report, and treated it as a yes/no variable. 
Finally, given the size and structure of our trial, pH testing was not part of the study design. 
However, reflux testing has since been shown not to predict PPI-REE status (12, 14), and 
subjects in clinical practice are classified by PPI administration, not pH test results.
This study has multiple strengths. This is the first prospective trial in the United States to 
explicitly assess the prevalences of EoE and PPI-REE using a clinical PPI trial, as 
recommended by current guidelines for the diagnosis of EoE (1, 2). It is also among the 
largest cohorts of incident esophageal eosinophilia and PPI-REE reported in the literature. 
Because the study was prospective, it also allowed for careful exclusion of other competing 
causes of esophageal eosinophilia, and in fact 2 cases of eosinophilic gastroenteritis 
overlapping with EoE were discovered due to systematic gastric and duodenal research 
protocol biopsies that were performed. Follow-up was compulsive, with only a single patient 
lost to follow-up.
In conclusion, we found that esophageal eosinophilia is common among patients undergoing 
upper endoscopy, and that after a PPI trial, nearly a quarter of patients with dysphagia had 
EoE, and PPI-REE was almost as common, accounting for over one-third of those with ≥15 
eos/hpf. Clinical, endoscopic, and histologic features could not distinguish the two groups at 
baseline prior to the PPI trial. This implies that novel methods are needed to distinguish 
these populations, with the ultimate goal of eliminating the requirement for a PPI trial from 
the diagnostic algorithm for EoE. However, given the current state of knowledge, these 
findings emphasize the necessity of a PPI trial as per current guidelines to accurately 
diagnose EoE. This is important clinically for patient care, but also crucial in research 
studies of epidemiology and treatment outcomes of patients with EoE to ensure interpretable 
results are generated from homogenous patient groups. Because there could be conceptual 
concerns with requiring a response to a pharmacologic agent in a disease definition, future 
investigations, potentially with molecular diagnostic methods, will be needed to clarify 
whether some patients with PPI-REE are a sub-phenotype of EoE, and whether EoE could 
eventually be diagnosed without a PPI trial.
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What is current knowledge?
• Esophageal eosinophilia is increasingly recognized and gastroenterologists need 
to identify the underlying cause of inflammation.
• Proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a newly 
recognized entity that must be differentiated from eosinophilic esophagitis 
(EoE), but little is known about this condition.
What is new here?
• In this prospective cohort of patients undergoing upper endoscopy, esophageal 
eosinophilia was found commonly, particularly in patients with dysphagia where 
it was seen nearly 40% of the time.
• 23% of subjects with dysphagia were confirmed to have EoE after a PPI trial.
• 36% of subjects with esophageal eosinophilia were found to have PPI-REE.
• It was difficult to distinguish PPI-REE and EoE prior to a PPI trial, and no 
feature independently predicted PPI-REE status.
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Patient flow through the study.
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Table 1
Characteristics of the study population
Subjects without esophageal 
eosinophilia (n = 155)
Subjects with esophageal 
eosinophilia* (n = 66)
p
Age at diagnosis (mean ± SD) 53.7 ± 15.1 40.5 ± 12.3 < 0.001
Male (n, %) 58 (37) 48 (73) < 0.001
White (n, %) 118 (77) 61 (92) 0.006
Symptoms/EGD indication (n, %)
 Dysphagia 109 (70) 64 (97) < 0.001
 Heartburn 25 (16) 5 (8) 0.09
 Abdominal pain 23 (15) 1 (2) 0.004
 Nausea/vomiting 6 (4) 1 (2) 0.36
EGD findings (n, %)
 Normal 36 (23) 1 (2) < 0.001
 Rings 23 (15) 52 (79) < 0.001
 Stricture 30 (19) 20 (30) 0.08
 Narrowing 8 (5) 19 (29) < 0.001
 Furrows 10 (6) 51 (77) < 0.001
 Crêpe-paper 0 (0) 4 (6) 0.002
 White plaques/exudates 9 (6) 26 (39) < 0.001
 Decreased vascularity 4 (3) 13 (20) < 0.001
 Erosive esophagitis 28 (18) 7 (11) 0.17
 Schatzki’s ring 12 (8) 6 (9) 0.75
 Hiatal hernia 47 (31) 14 (21) 0.16
 Dilation performed 52 (34) 20 (30) 0.64
PPI use on baseline exam 103 (71) 0 (0) < 0.001
Maximum eosinophil count (mean ± SD)† 3.2 ± 11.2 60.3 ± 41.9 < 0.001
Peripheral eosinophils (mean cells x 109/L ± SD) 0.18 ± 0.14 0.29 ± 0.21 < 0.001
IgE levels (mean kU/L ± SD) 141 ± 319 231 ± 414 0.10
*
Patients with EoE overlapping with eosinophilic gastroenteritis (n = 2) are excluded from esophageal eosinophilia group for analysis.
†
Eosinophil counts presented in eosinophils per high-power field (eos/hpf), for a hpf size of 0.24 mm2. For the esophageal eosinophil group, this 
value it the baseline count for the 48 subjects who had a PPI-naïve baseline endoscopy.
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Table 2
Characteristics of subjects with PPI-REE vs EoE
PPI-REE (n = 24) EoE (n = 41) p
Age at diagnosis (mean ± SD) 48.3 ± 10.9 35.9 ± 11.0 < 0.001
Male (n, %) 21 (88) 26 (63) 0.04
White (n, %) 21 (88) 39 (95) 0.27
Symptoms/EGD indication (n, %)
 Dysphagia 23 (96) 40 (98) 0.70
 Heartburn 2 (8) 3 (7) 0.88
 Abdominal pain 0 (0) 1 (2) 0.44
 Nausea/vomiting 1 (4) 0 (0) 0.19
EGD findings (n, %)*
 Normal 1 (4) 0 (0) 0.31
 Rings 15 (63) 24 (100) 0.001
 Stricture 6 (25) 8 (33) 0.56
 Narrowing 2 (8) 8 (33) 0.03
 Furrows 14 (58) 22 (92) 0.008
 Crêpe-paper 1 (4) 2 (8) 0.55
 White plaques/exudates 8 (33) 10 (42) 0.55
 Decreased vascularity 0 (0) 4 (17) 0.04
 Erosive esophagitis 5 (21) 2 (8) 0.22
 Schatzki’s ring 5 (21) 1 (4) 0.01
 Hiatal hernia 7 (29) 7 (29) 0.99
 Dilation performed 9 (38) 6 (25) 0.35
Maximum eosinophil counts (mean ± SD)†
 Before PPI trial* 58.3 ± 50.8 62.6 ± 29.8 0.74
 After PPI trial 8.6 ± 4.9 108.0 ± 113.5 < 0.001
Peripheral eosinophils (mean cells x 109/L, ± SD) 0.21 ± 0.11 0.35 ± 0.24 0.01
IgE levels (mean kU/L ± SD) 230 ± 541 238 ± 322 0.95
*
n = 24 for the EoE group for baseline endoscopic findings and the baseline eosinophilic counts; the remaining 17 EoE subjects had their index 
endoscopy after the PPI trial, so pre-PPI endoscopic findings and histology data are not available.
†
Eosinophil counts presented in eosinophils per high-power field (eos/hpf), for a hpf size of 0.24 mm2
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